|
|
|
|
| LEADER |
00000cam a2200000Ii 4500 |
| 001 |
SCIDIR_ocn959411508 |
| 003 |
OCoLC |
| 005 |
20231120112139.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
160928s2016 mau o 001 0 eng d |
| 040 |
|
|
|a OPELS
|b eng
|e rda
|e pn
|c OPELS
|d YDX
|d N$T
|d IDEBK
|d N$T
|d EBLCP
|d OCLCF
|d QCL
|d UPM
|d OCLCO
|d OCLCQ
|d D6H
|d OCLCQ
|d UKMGB
|d OCLCO
|d OCL
|d OCLCQ
|d OCLCO
|
| 015 |
|
|
|a GBB6E2085
|2 bnb
|
| 016 |
7 |
|
|a 018058785
|2 Uk
|
| 019 |
|
|
|a 959536597
|a 959595372
|a 959648617
|a 962414724
|
| 020 |
|
|
|a 9780128046364
|q (electronic bk.)
|
| 020 |
|
|
|a 0128046368
|q (electronic bk.)
|
| 020 |
|
|
|a 9780128047590
|q (electronic bk.)
|
| 020 |
|
|
|a 0128047593
|q (electronic bk.)
|
| 035 |
|
|
|a (OCoLC)959411508
|z (OCoLC)959536597
|z (OCoLC)959595372
|z (OCoLC)959648617
|z (OCoLC)962414724
|
| 050 |
|
4 |
|a R857.N34
|
| 060 |
|
4 |
|a QT 36.5
|
| 072 |
|
7 |
|a HEA
|x 012000
|2 bisacsh
|
| 072 |
|
7 |
|a HEA
|x 020000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 004000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 101000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 109000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 029000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 040000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 092000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 610.28
|2 23
|
| 245 |
0 |
0 |
|a Nanotechnology and the brain /
|c edited by Khuloud T. Al-Jamal.
|
| 264 |
|
1 |
|a Cambridge, MA :
|b Academic Press is an imprint of Elsevier,
|c 2016.
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a International review of neurobiology ;
|v volume 130
|
| 500 |
|
|
|a Includes index.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (ScienceDirect, viewed September 28, 2016).
|
| 505 |
0 |
|
|a Front Cover; Nanotechnology and the Brain; Copyright; Contents; Contributors; Preface; Chapter One: Recent Trends in Nanotechnology Toward CNS Diseases: Lipid-Based Nanoparticles and Exosomes for Targeted The ...; 1. Introduction; 2. Lipid-Based Nanoparticles for Nucleic Acid and Drug Delivery to the CNS; 2.1. Ischemic Stroke; 2.2. Neuropathic Pain; 2.3. Alzheimer�s Disease; 2.4. Parkinson�s Disease; 2.5. Machado-Joseph Disease; 2.6. Multiple Sclerosis; 2.7. CNS Tumors; 2.8. Other Neurological Disorders; 3. Exosomes as Delivery Systems for CNS Diseases; 4. Conclusions; Acknowledgments
|
| 505 |
8 |
|
|a 1. Introduction2. NPs for Brain Cancer; 2.1. Physiopathology; 2.1.1. Brain Tumors and Glioblastoma; 2.1.1.1. Brain Tumors; 2.1.1.2. Glioblastoma; 2.2. Standard Treatments; 2.2.1. Current GB Therapies; 2.2.1.1. Surgery; 2.2.1.2. Chemotherapy; 2.2.1.3. Radiotherapy; 2.2.2. Therapeutic Limitations; 2.3. NP-Based GB Therapy; 2.3.1. Advantages; 2.3.1.1. Suitable Drugs; 2.3.1.2. Pharmacokinetic Modulation; 2.3.1.3. Targeting; 2.3.1.4. Crossing Barrier Facilitation; 2.3.1.5. Theranostic Medicine; 2.3.1.6. Gene Therapy; 2.3.2. Preclinical Phase and Clinical Trials; 2.3.2.1. Preclinical Phase
|
| 505 |
8 |
|
|a 2.3.2.2. Clinical Trials2.3.3. Limits of NP-Based GB Therapies; 2.4. Novel NP-Based Approaches for GB Treatment; 2.5. Conclusion on the Application of Nanomedicine to GB Therapy; 3. NPs for Alzheimer�s Disease Therapy; 3.1. Physiopathology; 3.1.1. Neurodegenerative Diseases and Alzheimer�s Disease; 3.1.1.1. Neurodegenerative Diseases; 3.1.1.2. Alzheimer�s Disease; 3.2. Conventional Treatments; 3.2.1. Current Therapy and Research Strategies; 3.2.1.1. Therapeutics Based on ``Cholinergic Hypothesis��; 3.2.1.2. Therapeutics Based on ``Tau Cascade Hypothesi��s
|
| 505 |
8 |
|
|a 3.2.1.3. Therapeutics Based on ``Amyloid Cascade Hypothesis��3.2.2. Limitations of ADs Therapies; 3.3. NP-Based AD Therapies; 3.3.1. Nanotechnological Improvement and Innovation; 3.3.1.1. Nanotechnological Improvement; 3.3.1.2. Nanotechnological Innovation; 3.3.2. Preclinical Phase and Clinical Trials; 3.4. Conclusions on the Application of Nanomedicine to Alzheimer Disease Therapy; 4. Nanotechnology for the Treatment of Stroke; 4.1. Physiopathology of Stroke; 4.2. Current Stroke Therapies; 4.2.1. Thrombolysis; 4.2.2. Neuroprotective Therapy; 4.3. NP-Based Stroke Therapy; 4.3.1. Advantages
|
| 650 |
|
0 |
|a Nanomedicine.
|
| 650 |
|
0 |
|a Nanobiotechnology.
|
| 650 |
|
0 |
|a Nanotechnology.
|
| 650 |
|
2 |
|a Nanomedicine
|0 (DNLM)D050997
|
| 650 |
|
2 |
|a Nanotechnology
|0 (DNLM)D036103
|
| 650 |
|
6 |
|a Nanobiotechnologie.
|0 (CaQQLa)000286131
|
| 650 |
|
6 |
|a Nanom�edecine.
|0 (CaQQLa)201-0448752
|
| 650 |
|
6 |
|a Nanotechnologie.
|0 (CaQQLa)201-0225435
|
| 650 |
|
7 |
|a HEALTH & FITNESS / Holism
|2 bisacsh
|
| 650 |
|
7 |
|a HEALTH & FITNESS / Reference
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Alternative Medicine
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Atlases
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Essays
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Family & General Practice
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Holistic Medicine
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Osteopathy
|2 bisacsh
|
| 650 |
|
7 |
|a Nanotechnology
|2 fast
|0 (OCoLC)fst01032639
|
| 650 |
|
7 |
|a Nanobiotechnology
|2 fast
|0 (OCoLC)fst01894713
|
| 650 |
|
7 |
|a Nanomedicine
|2 fast
|0 (OCoLC)fst01744350
|
| 700 |
1 |
|
|a Al-Jamal, Khuloud,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|z 9780128046364
|z 0128046368
|w (OCoLC)950450178
|
| 830 |
|
0 |
|a International review of neurobiology ;
|v v. 130.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/00747742/130
|z Texto completo
|
